How Long Is Retatrutide Stable After Reconstitution?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

Key Takeaways

• Retatrutide is investigational and not FDA-approved. FormBlends does not supply retatrutide. Direct stability data are not yet published; this material reasons from peptide chemistry principles and analogous approved peptides
• Reconstituted peptide stored at 2-8 C typically retains usable potency for 14 to 28 days based on data from semaglutide and tirzepatide
• USP 797 sets the default beyond-use date at 14 days for low-risk refrigerated compounded sterile preparations. Extensions require documented stability data
• At room temperature, the BUD compresses to 48 hours under USP 797 default categories
• Beyond-use dates assume proper storage. Significant temperature excursions invalidate them even before calendar expiration

Direct answer

Direct stability data on retatrutide are not yet published. By analogy with structurally similar approved peptides (semaglutide and tirzepatide), reconstituted retatrutide stored at 2-8 degrees Celsius is expected to retain potency for 14 to 28 days. USP 797 sets the default refrigerated beyond-use date at 14 days for low-risk compounded sterile preparations; pharmacies can extend to 28 days with documented stability work. At room temperature, the default BUD is 48 hours. Retatrutide is investigational; FormBlends does not supply it. This is educational context, not a guide for personal preparation.

Table of contents

1. Why this question has multiple right answers
2. What changes the moment water enters the vial
3. The USP 797 beyond-use date table
4. What semaglutide and tirzepatide stability data show
5. The diluent matters
6. The interaction of temperature, time, and integrity
7. What invalidates the BUD before its calendar date
8. What clinical trials assume about post-reconstitution stability
9. How to read your dispensing label
10. FAQ
11. Sources

Why this question has multiple right answers

The question "how long does retatrutide last after reconstitution" sounds like it should have a single number. It doesn't. The answer depends on several variables:

• Storage temperature (refrigerated, room temperature, frozen, hot)
• Diluent type (BWFI with preservative vs SWFI without)
• USP 797 risk category of the preparation
• Whether the pharmacy has documented stability data justifying extended BUDs
• Whether the vial has experienced any temperature excursions
• Light exposure history
• How many times the septum has been punctured

The dispensing label encodes most of this. The pharmacy chooses the BUD based on the preparation method, storage condition, and available stability data. Patients who follow the labeled storage instructions can rely on the labeled BUD. Patients who do not have a properly labeled vial are in a different situation, one where reasoning from first principles is the only available approach.

What changes the moment water enters the vial

Lyophilized peptide is in a glass-like solid state, with most of the water removed during freeze-drying. In that state, most degradation reactions cannot proceed because they require water as a reactant or as a medium for molecular motion.

When bacteriostatic water for injection is added to reconstitute the peptide, several things happen at once:

• Water molecules diffuse into the lyophilized cake and dissolve the peptide
• The peptide is now in aqueous solution, free to interact with itself and with the vial surfaces
• Chemical degradation pathways resume: hydrolysis of peptide bonds, oxidation of methionine, deamidation of asparagine and glutamine
• Physical degradation pathways become accessible: aggregation at the air-water interface, surface adsorption
• If the diluent is BWFI, the benzyl alcohol preservative limits microbial growth, but does not block chemical degradation of the peptide

From this moment, the clock starts. Stability is measured in days to weeks rather than months to years. The exact rate depends on temperature, formulation, and storage handling.

The USP 797 beyond-use date table

USP General Chapter 797 sets default BUDs for compounded sterile preparations based on risk category and storage condition. The relevant table for a reconstituted peptide (typically classified as low-risk):

Storage condition	Default BUD (low-risk CSP)	Notes
Controlled room temperature (20-25 C)	48 hours	Used for immediate-use preparations
Refrigerated (2-8 C)	14 days	Standard for most compounded peptides without pharmacy-specific stability data
Frozen (-20 C or colder)	45 days	Rarely used for reconstituted peptides because freezing damages structure

These are the floor. Pharmacies with documented stability-indicating assay data on a specific peptide-formulation-storage combination can extend BUDs. The 28-day refrigerated BUD common in compounded semaglutide and tirzepatide dispensing reflects this kind of pharmacy-specific work.

For retatrutide, the legal-compounding question precedes the BUD question. Retatrutide is not on FDA's bulk substances list approved for 503A compounding as of May 2026, which means most pharmacies cannot legally compound it. The BUD discussion assumes a hypothetical legal compounding scenario or a clinical trial pharmacy context.

What semaglutide and tirzepatide stability data show

Although retatrutide-specific data are not yet available, related approved peptides provide useful reference points:

Semaglutide: FDA-approved formulations (Ozempic, Wegovy) carry post-first-use windows of 56 days (Ozempic) or 28 days (Wegovy) at room temperature up to 30 C. Compounded semaglutide preparations have demonstrated greater than 95% potency retention through 28 days at refrigeration in multiple published stability studies.

Tirzepatide: FDA-approved formulations (Mounjaro, Zepbound) are supplied in single-use prefilled pens; in-use windows are 21 days at room temperature up to 30 C. Compounded tirzepatide stability data show similar refrigerated stability profiles.

Liraglutide: A daily GLP-1 with established stability data, used as a comparator. In-use stability windows are 30 days at room temperature for Victoza and Saxenda. Compounded liraglutide preparations are less commonly used but show comparable stability.

Retatrutide shares the basic peptide architecture (~39 amino acids, fatty acid acylation) with these molecules. The reasonable expectation is similar stability behavior. The reasonable caveat is that "expected" is not the same as "measured." Until published stability data emerge, the conservative 14-28 day refrigerated window is a defensible baseline.

The diluent matters

The choice of diluent affects how long the reconstituted vial can be used:

Bacteriostatic water for injection (BWFI): Contains 0.9% benzyl alcohol as a preservative. The preservative inhibits bacterial growth between septum punctures, supporting multi-dose use over weeks. Standard for compounded multi-dose peptide preparations.

Sterile water for injection (SWFI): No preservative. Appropriate for single-dose, immediate-use preparations only. Beyond-use date is much shorter for multi-dose vials reconstituted with SWFI because microbial contamination risk rises with each puncture.

0.9% sodium chloride for injection: Sometimes used for specific peptide formulations where the salt environment improves stability. Less common for GLP-1 family peptides than BWFI.

For retatrutide in an educational context, BWFI is the standard choice for any preparation intended to support more than a single dose. The 14-28 day window assumes BWFI as the diluent.

The interaction of temperature, time, and integrity

Post-reconstitution stability is not a single number; it is a curve. Potency declines gradually over time, with the rate of decline depending on temperature. The beyond-use date is a conservative point on that curve where the pharmacy decides the preparation should no longer be used.

For a hypothetical retatrutide-like peptide stored at 2-8 C:

• Day 0-14: Greater than 95% potency, no visible changes, no aggregation
• Day 14-28: 90-95% potency, no visible changes in most preparations, low aggregation
• Day 28-42: Potency may dip below 90%, subtle aggregation may begin, still typically clear visually
• Day 42+: Cumulative degradation becomes more pronounced; visible changes may appear in some preparations

These are illustrative rather than measured for retatrutide specifically. The pattern is consistent across peptide families.

At higher temperatures, the curve compresses. At 25 C, the same total degradation reaches in days what would take weeks at 4 C. This is why temperature excursions are not just calendar penalties; they shift the entire stability curve forward.

What invalidates the BUD before its calendar date

The beyond-use date is contingent on proper storage. Several events can invalidate the BUD even before the calendar date arrives:

• Sustained exposure above 25 C (a day or more at room temperature, a hot car)
• Any exposure below 0 C (accidental freezing)
• Prolonged exposure to direct sunlight or bright indoor light
• Mechanical stress: vigorous shaking, dropping the vial repeatedly, transport without padding
• Visible cloudiness, color change, or particulates regardless of calendar date
• Septum compromise (cracked or visibly damaged rubber stopper)
• Loss of refrigeration during power outage exceeding the cooler maintenance window

Patients who experience any of these events should document the situation and contact the dispensing pharmacy. The pharmacy can advise whether the affected vial should be replaced.

What clinical trials assume about post-reconstitution stability

The Phase 2 retatrutide trial (Jastreboff et al., New England Journal of Medicine 2023) used sponsor-supplied investigational product. Trial design assumed sponsor-defined stability windows for the product as supplied, with chain-of-custody documentation from manufacturer through site dispensing to patient self-administration.

Sponsor-prepared product is not reconstituted at the trial site or by the patient. The stability window applies to the as-supplied formulation under specified storage conditions. Patient instructions for home storage typically include:

• Refrigerate at 2-8 C, do not freeze, protect from light
• Bring product to room temperature briefly before injection (some protocols)
• Return unused product at end of dosing cycle for accountability
• Report temperature excursions to the trial site for evaluation

The trial-context numbers do not translate directly to compounded preparations. Sponsor formulations are specifically engineered for stability, with excipients, pH buffers, and antioxidants optimized over years of formulation work. Compounded preparations using research-grade or compounded active ingredient may not have the same stability profile.

How to read your dispensing label

For patients receiving any compounded peptide preparation (semaglutide or tirzepatide, since retatrutide is not legally dispensed for outpatient use in the U.S. as of May 2026):

Find these elements on the label:

• Beyond-use date (your "discard after" date)
• Storage instructions (typically "refrigerate, do not freeze, protect from light")
• Concentration (mg/mL)
• Dose volume per injection
• Reconstitution date or date of preparation
• Pharmacy contact information

Key things to remember:

• The BUD assumes proper storage throughout. If you have had a refrigeration failure or significant temperature excursion, the BUD may no longer apply
• The label is the source of truth. If something seems inconsistent (label says one concentration, but the dose volume on the instructions implies another), call the pharmacy
• Visual changes (cloudiness, discoloration, particulates) override the BUD. Discard regardless of calendar date

FAQ

How long does retatrutide last after reconstitution? Direct data are not yet published. By analogy with semaglutide and tirzepatide, reconstituted peptide at 2-8 C typically retains potency for 14 to 28 days. Retatrutide is investigational; FormBlends does not supply it.

How long at room temperature? USP 797 sets a 48-hour BUD for low-risk CSPs at controlled room temperature. Pharmacies favor refrigerated storage to extend usable life.

Why is post-reconstitution stability shorter than lyophilized stability? Water participates in most peptide degradation reactions. Lyophilized peptide is stable for months because there is no water; reconstituted peptide is back in aqueous solution and degrades over weeks.

Can the BUD be extended past 28 days? Only with documented peptide-specific stability data. The pharmacy must perform stability-indicating assays demonstrating potency retention.

What signs indicate the reconstituted product has gone bad? Cloudiness, color change, or visible particulates are rejection criteria. Subtle degradation may not be visible; beyond-use date discipline matters rather than relying solely on appearance.

Does the diluent type affect stability? Yes. BWFI with preservative supports longer multi-dose use. SWFI without preservative is appropriate for single-dose, immediate-use preparations only.

How does temperature excursion affect the BUD? Significant excursions invalidate the BUD even before calendar expiration. Brief excursions are usually tolerated; sustained excursions can require the affected vial to be discarded.

Does freezing extend stability? No. Reconstituted peptide should not be frozen. Ice crystal damage to structure is generally not reversible.

Should I trust online claims of 60-90 day post-reconstitution stability? Be skeptical without supporting data. Established compounding pharmacies use 14-28 day refrigerated BUDs based on USP 797 standards. Claims of much longer stability without published stability-indicating assay data are not supportable.

What if I miss a dose and need to use product near the BUD? Product within its labeled BUD is generally fine. Product past the BUD should not be used. If you are uncertain about your storage history, contact the dispensing pharmacy.

Related guides

• How Long Does Reconstituted 10 mg Retatrutide Stay Stable?
• How Long Is Retatrutide Stable Once Reconstituted? What Peptide Stability Principles Suggest
• Retatrutide Before and After: Clinical Trial Weight Loss Data
• Retatrutide for Weight Regain After Bariatric: What Research Shows
• Do You Gain Weight Back After Stopping Retatrutide
• Retatrutide Maintenance: What Comes After Weight Loss
• Tool: reconstitution calculator

Sources

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526.
2. United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding: Sterile Preparations. 2023 revision.
3. FDA Prescribing Information: Ozempic (semaglutide injection). Novo Nordisk. Updated 2024.
4. FDA Prescribing Information: Wegovy (semaglutide injection). Novo Nordisk. Updated 2024.
5. FDA Prescribing Information: Mounjaro (tirzepatide injection). Eli Lilly. Updated 2024.
6. FDA Prescribing Information: Zepbound (tirzepatide injection). Eli Lilly. Updated 2024.
7. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of Protein Pharmaceuticals: An Update. Pharmaceutical Research. 2010;27(4):544-575.
8. Hawe A, Wiggenhorn M, van de Weert M, et al. Forced Degradation of Therapeutic Proteins. Journal of Pharmaceutical Sciences. 2012;101(3):895-913.
9. American Society of Health-System Pharmacists. ASHP Guidelines on Compounding Sterile Preparations. 2023.
10. International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products.
11. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in 503A Pharmacy Compounding. Updated 2025.
12. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends operates a digital health platform that connects patients to U.S.-licensed providers and state-licensed pharmacies. We do not manufacture, prescribe, or dispense medication. We do not sell or supply retatrutide. All clinical decisions belong to the patient and an independent licensed prescriber.

Compounded Medication Notice. Compounded medications from state-licensed 503A pharmacies follow USP 797 standards but are not FDA-approved and have not undergone the agency review applied to brand-name drugs. They are not interchangeable with FDA-approved products.

Results Disclaimer. Post-reconstitution stability information here is drawn from USP 797 framework, peptide chemistry literature, and analogous approved peptides. Retatrutide-specific stability data are not yet published because the product is investigational. This material is educational, not a guide for personal preparation.

Trademark Notice. Retatrutide is the developmental designation for an investigational compound from Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends has no affiliation or endorsement with the named companies.